Get started
Author

Yuki Kugiyama

Observed names: Y. Kugiyama, YUKI KUGIYAMA
ORCID: 0009-0008-2849-9057
Observed ORCID: 0009-0008-2849-9057
OpenAlex ID: A5055304159
Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients
2014 · Kazumi Yamasaki, Masakuni Tateyama, et al. · Hepatology · 232
PDF
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
2016 · Satoru Hashimoto, Hiroshi Yatsuhashi, et al. · PLoS ONE · 97
PDF
Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response
2015 · Ryu Sasaki, Kazumi Yamasaki, et al. · PLoS ONE · 81
PDF
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
2019 · Ryu Sasaki, Masanori Fukushima, et al. · Cancers · 54
PDF
Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
2017 · Yasuhiko Nakao, Satoru Hashimoto, et al. · Journal of Hepatology · 38
Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
2022 · Ryu Sasaki, Kazuyoshi Nagata, et al. · Cancers · 37
PDF
Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma
2020 · Shigemune Bekki, Satoru Hashimoto, et al. · PLoS ONE · 25
PDF
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis
2024 · Yuki Hitomi, Kazuko Ueno, et al. · Hepatology · 14
Analysis of the Hepatic Functional Reserve, Portal Hypertension, and Prognosis of Patients With Human Immunodeficiency Virus/Hepatitis C Virus Coinfection Through Contaminated Blood Products in Japan
2014 · S. Eguchi, M. Takatsuki, et al. · Transplantation Proceedings · 12
PDF
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
2024 · Atsumasa Komori, Yuki Kugiyama · Clinical and Molecular Hepatology · 10
PDF
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
2025 · Risako Kohya, Goki Suda, et al. · JHEP Reports · 9
PDF
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2025 · Masatsugu Ohara, Goki Suda, et al. · Hepatology International · 8
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib
2021 · RYU SASAKI, MASANORI FUKUSHIMA, et al. · Anticancer Research · 7
PDF
Clinical statement on the PBC-AIH overlap 2024 The Intractable Hepato-Biliary Disease Study Group was supported by the Ministry of Health, Labor, and Welfare of Japan
2025 · Yuki Kugiyama, Kazuhito Kawata, et al. · Kanzo · 4
PDF
Zinc supplementation with polaprezinc was associated with improvements in albumin, prothrombin time activity, and hemoglobin in chronic liver disease
2023 · Seigo Abiru, Yuki Kugiyama, et al. · Journal of Clinical Biochemistry and Nutrition · 4
PDF
Evaluation of portal hypertension and prognosis of patients with HIV/HCV co-infection through comtaminated blood product
2012 · Mitsuhisa Takatsuki, Susumu Eguchi, et al. · Kanzo · 3
PDF
Lactitol may improve the prognosis of hepatocellular carcinoma through the proliferation of Megasphaera as well as Bifidobacterium
2025 · Seigo Abiru, Yuki Kugiyama, et al. · Frontiers in Medicine · 2
PDF
Real-world prospective comparison of sorafenib and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A multicenter study in Japan (KSCC HAMRET).
2026 · Sadahisa Ogasawara, Shinji Itoh, et al. · Journal of Clinical Oncology · 1
Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey
2025 · Yuki Kugiyama, Masanori Abe, et al. · Hepatology Research · 1
PDF
Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct‐acting antivirals
2025 · Tomoyuki Suehiro, Hideko Kozuru, et al. · Hepatology Research · 1
PDF
On‐Treatment Reassessment of Type IV Collagen 7S and M2BPGi‐Qt Improves Long‐Term Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis B
2026 · Kazumi Yamasaki, Hideko Kozuru, et al. · Hepatology Research
PDF
Baseline and Longitudinal Liver Stiffness Measurement Predict Outcomes in Primary Biliary Cholangitis: A Multicenter Study
2026 · Yuki Yamashita, Takefumi Kimura, et al. · Hepatology Research
WED-638 Combined use of aMAP risk score and M2BPGi for stratifying hepatocellular carcinoma risk after SVR following direct-acting antiviral therapy
2026 · Tomoyuki Suehiro, Tomohito Kojima, et al. · Journal of Hepatology
WED-618 Evaluation of clinical performance and utility of the combined HCV antigen-antibody assay (HCV Duo)
2026 · Kazumi Yamasaki, Tatsuya Fujino, et al. · Journal of Hepatology
FRI-256 Durable response is associated with long-term survival even in patients with poor hepatic reserve after Atezolizumab plus Bevacizumab: a multicenter 3-year overall survival cohort with a 6-month landmark analysis
2026 · Masatsugu Ohara, Goki Suda, et al. · Journal of Hepatology
Works count: 45
Citation count: 640
H-index: 10
I10-index: 10
Year
Topic
Type